Literature DB >> 3418382

Ten-year survival among patients with supratentorial astrocytomas grade III and IV.

L G Salford1, A Brun, S Nirfalk.   

Abstract

The Swedish Cancer Registry, in a linkage with the Swedish Registry of Statistics, was used to trace all patients operated on in Southern Sweden for histopathologically verified malignant primary central nervous system tumors during the years 1958 to 1975. Patients surviving 10 years after the operation were identified, and their original surgical specimens were reexamined. Six (0.5%) of 1147 patients were shown to have survived for between 12 and 28 years after surgery for supratentorial astrocytomas grade III and IV. All six patients are in good condition, without signs of tumor recurrence. The only obvious common denominator for the survivors is their youth at operation. Three patients were 7 to 11 years old at surgery, and none was older than 38 years. It is concluded that a cure may be possible in exceptional patients with the "incurable" astrocytoma grade III and IV.

Entities:  

Mesh:

Year:  1988        PMID: 3418382     DOI: 10.3171/jns.1988.69.4.0506

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  21 in total

1.  Long-term survival in a patient with supratentorial glioblastoma: clinical considerations.

Authors:  L Cervoni; P Celli; M Salvati
Journal:  Ital J Neurol Sci       Date:  1998-08

2.  Should we reoperate for recurrent high-grade astrocytoma?

Authors:  Jin-fang Xu; Jun Fang; Yi Shen; Jian-min Zhang; Wei-guo Liu; Hong Shen
Journal:  J Neurooncol       Date:  2011-05-17       Impact factor: 4.130

3.  O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.

Authors:  Yukihiko Sonoda; Michiko Yokosawa; Ryuta Saito; Masayuki Kanamori; Yoji Yamashita; Toshihiro Kumabe; Mika Watanabe; Teiji Tominaga
Journal:  Int J Clin Oncol       Date:  2010-03-16       Impact factor: 3.402

Review 4.  Estramustine in malignant glioma.

Authors:  A T Bergenheim; R Henriksson; J M Piepmeier; D Yoshida
Journal:  J Neurooncol       Date:  1996-10       Impact factor: 4.130

5.  TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme.

Authors:  J A Kraus; M Wenghoefer; N Glesmann; S Mohr; M Beck; M C Schmidt; R Schröder; U Berweiler; W Roggendorf; S Diete; K Dietzmann; K Heuser; B Müller; R Fimmers; A von Deimling; U Schlegel
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

Review 6.  Mitogens as motogens.

Authors:  M R Chicoine; D L Silbergeld
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

7.  Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma.

Authors:  Maryam Shabihkhani; Donatello Telesca; Masoud Movassaghi; Yalda B Naeini; Kourosh M Naeini; Seyed Amin Hojat; Diviya Gupta; Gregory M Lucey; Michael Ontiveros; Michael W Wang; Lauren S Hanna; Desiree E Sanchez; Sergey Mareninov; Negar Khanlou; Harry V Vinters; Marvin Bergsneider; Phioanh Leia Nghiemphu; Albert Lai; Linda M Liau; Timothy F Cloughesy; William H Yong
Journal:  J Neurooncol       Date:  2017-02-04       Impact factor: 4.130

8.  Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme.

Authors:  J A Kraus; N Glesmann; M Beck; D Krex; T Klockgether; G Schackert; U Schlegel
Journal:  J Neurooncol       Date:  2000-06       Impact factor: 4.130

9.  Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics.

Authors:  M Morita; M K Rosenblum; M H Bilsky; R A Fraser; M R Rosenfeld
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

10.  Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene--a phase I/II clinical protocol.

Authors:  H Ren; T Boulikas; K Lundstrom; A Söling; P C Warnke; N G Rainov
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.